Categories
Life Sciences Consumer Goods Materials and Chemicals Construction & Manufacturing Food and Beverages Energy and Power Semiconductor and Electronics Automotive and Transportation ICT & Media Aerospace & Defense BFSI

Int'l : +1-503-894-6022 | Toll Free : +1-800-792-5285 | help@alliedmarketresearch.com

Gene Sequencing Market by Product Type (Consumables, Instruments, Services), by Application (Oncology and Reproductive Health, Clinical Investigation, Consumer Genomics, Metagenomics, Others), by Workflow Type (Pre-Sequencing, Sequencing, Data Analysis) and by End User (Academic Research, Clinical Research, Hospitals, Pharmaceutical Companies, Others): Global Opportunity Analysis and Industry Forecast, 2023-2032

A13358

Pages: NA

Charts: NA

Tables: NA

Gene sequencing is a procedure in which the nucleotides are identified in the DNA of an organism. This method is used to learn about the genome of the organism as a whole and to identify specific areas of interest or required. Low cost, precise results, high accuracy, and rapid results are the key features of gene sequencing technique. Gene sequencing is used to execute various applications such as oncology studies, reproductive health, clinical investigation, and others. It consists of widely replaced conventional tools of genomics, especially, microarray, genotyping, and others. Maxam-Gilbert Sequencing and Sanger Sequencing are the types of gene sequencing.  

COVID-19 Impact Analysis             

COVID-19 is an infectious disease that originated in Hubei province of the Wuhan city in China in late December. The highly contagious disease, caused by a virus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is transmitted from human to human. Since the outbreak in December 2019, the disease has spread to almost 213 countries around the globe with the World Health Organization declaring it a public health emergency on March 11, 2020.

At the early phase of COVID-19 pandemic, there was no availability of specific diagnostic tests to detect the disease in patients. Alternative diagnostic tests were used initially but were not much effective. This unavailability of specific COVID-19 diagnostic tests presented lucrative opportunities for diagnostic manufacturers to introduce their COVID-19 diagnostic kits. Many leading players as well as some start-ups from various countries utilized this opportunity and introduced COVID-19 diagnostics kits into local as well as global market. These players achieved edge over other diagnostics players capitalizing the opportunity from demand for COVID-19 diagnostic tests, which, in turn, helps them in maintaining their revenues in such a crisis.

Owing to such factors, COVID 19 is expected to have a significant impact on the gene sequencing market.

Top Impacting Factors

  • Increase in number of genome mapping programs across the globe, rise in demand by oncology department, surge in awareness regarding early diagnosis & detection of chronic diseases, and rise in next generation sequencing in diagnostic procedures are the key factors that drive the growth of the market.
  • In addition, launch of novel third generation sequencing procedure such as Nanopore & Single- Molecule Real-Time sequencing, continuous technological innovations in sequencing market through R & D activities, surge in adoption of highly advanced diagnostic tests, rise in demand of cost effective diagnostic procedures, and joint ventures & agreements between key market players are expected to boost the growth of the market.
  • However, lack of awareness regarding sequencing diagnostic tests can hinder the growth of the market.
  • Contrarily, government support through product approval and improved reimbursement policies for diagnostic tests are expected to offer lucrative opportunities for the expansion of the market.

Market Trends

New Product Launches to Flourish the Market

In 2021, Centogene announced launch of its new CentoXome product. This product is used full in whole exome sequencing procedures in gene. Moreover, rare and complicated or unsolved diseases can be diagnosed with the help of this product.

In 2019, Thermo Fisher Scientific launched Ion Torrent Genexus System. This product is fully integrated next generation sequencing featuring specimen to report workflow and delivers results economically in a single day. This product can be used in DNA mutation analysis and RNA fusion transcripts in myeloid samples.

Key Benefits of the Report

  • This study presents the analytical depiction of gene sequencing market industry along with the current trends and future estimations to determine the imminent investment pockets.
  • The report presents information related to key drivers, restraints, and opportunities along with detailed analysis of the market share.
  • The current market is quantitatively analyzed to highlight the market growth scenario.
  • Porter’s five forces analysis illustrates the potency of buyers & suppliers in the market.
  • The report provides a detailed market analysis depending on competitive intensity and how the competition will take shape in coming years.

Questions Answered in the Gene Sequencing Market Report                     

  • Which are the leading players active in the gene sequencing market?
  • What are the current trends that will influence the market in the next few years?
  • What are the driving factors, restraints, and opportunities of the market?
  • What future projections would help in taking further strategic steps?
  • What is "gene sequencing"?
  • What is "gene sequencing" market prediction in the future?
  • Who are the leading global players in the "gene sequencing" market?
  • What are the current trends and predicted trends?
  • What are the key benefits of the "gene sequencing" market report?

Key Market Segments

  • By Product Type
    • Consumables
    • Instruments
    • Services
  • By Application
    • Oncology and Reproductive Health
    • Clinical Investigation
    • Consumer Genomics
    • Metagenomics
    • Others
  • By Workflow Type
    • Pre-Sequencing
    • Sequencing
    • Data Analysis
  • By End User
    • Academic Research
    • Clinical Research
    • Hospitals
    • Pharmaceutical Companies
    • Others
  • By Region
    • North America
      • U.S.
      • Canada
      • Mexico
    • Europe
      • France
      • Germany
      • Italy
      • Spain
      • UK
      • Rest of Europe
    • Asia-Pacific
      • China
      • Japan
      • India
      • South Korea
      • Australia
      • Rest of Asia-Pacific
    • LAMEA
      • Brazil
      • South Africa
      • Saudi Arabia
      • Rest of LAMEA


Key Market Players

  • Illumina, Inc.
  • PierianDx
  • Intrexon Bioinformatics Germany GmbH
  • Pacific Biosciences of California, Inc.
  • F. Hoffmann-La Roche Ltd.
  • QIAGEN
  • Myriad Genetics
  • Thermo Fisher Scientific, Inc.
  • Agilent Technologies, Inc.
  • Eurofins Scientific
  • CHAPTER 1: INTRODUCTION

    • 1.1. Report Description

    • 1.2. Key Market Segments

    • 1.3. Key Benefits

    • 1.4. Research Methodology

      • 1.4.1. Primary Research

      • 1.4.2. Secondary Research

      • 1.4.3. Analyst Tools and Models

  • CHAPTER 2: EXECUTIVE SUMMARY

    • 2.1. CXO Perspective

  • CHAPTER 3: MARKET LANDSCAPE

    • 3.1. Market Definition and Scope

    • 3.2. Key Findings

      • 3.2.1. Top Investment Pockets

      • 3.2.2. Top Winning Strategies

    • 3.3. Porter's Five Forces Analysis

      • 3.3.1. Bargaining Power of Suppliers

      • 3.3.2. Threat of New Entrants

      • 3.3.3. Threat of Substitutes

      • 3.3.4. Competitive Rivalry

      • 3.3.5. Bargaining Power among Buyers

    • 3.5. Market Dynamics

      • 3.5.1. Drivers

      • 3.5.2. Restraints

      • 3.5.3. Opportunities

  • CHAPTER 4: GENE SEQUENCING MARKET, BY PRODUCT TYPE

    • 4.1. Market Overview

      • 4.1.1 Market Size and Forecast, By Product Type

    • 4.2. Consumables

      • 4.2.1. Key Market Trends, Growth Factors and Opportunities

      • 4.2.2. Market Size and Forecast, By Region

      • 4.2.3. Market Share Analysis, By Country

    • 4.3. Instruments

      • 4.3.1. Key Market Trends, Growth Factors and Opportunities

      • 4.3.2. Market Size and Forecast, By Region

      • 4.3.3. Market Share Analysis, By Country

    • 4.4. Services

      • 4.4.1. Key Market Trends, Growth Factors and Opportunities

      • 4.4.2. Market Size and Forecast, By Region

      • 4.4.3. Market Share Analysis, By Country

  • CHAPTER 5: GENE SEQUENCING MARKET, BY APPLICATION

    • 5.1. Market Overview

      • 5.1.1 Market Size and Forecast, By Application

    • 5.2. Oncology And Reproductive Health

      • 5.2.1. Key Market Trends, Growth Factors and Opportunities

      • 5.2.2. Market Size and Forecast, By Region

      • 5.2.3. Market Share Analysis, By Country

    • 5.3. Clinical Investigation

      • 5.3.1. Key Market Trends, Growth Factors and Opportunities

      • 5.3.2. Market Size and Forecast, By Region

      • 5.3.3. Market Share Analysis, By Country

    • 5.4. Consumer Genomics

      • 5.4.1. Key Market Trends, Growth Factors and Opportunities

      • 5.4.2. Market Size and Forecast, By Region

      • 5.4.3. Market Share Analysis, By Country

    • 5.5. Metagenomics

      • 5.5.1. Key Market Trends, Growth Factors and Opportunities

      • 5.5.2. Market Size and Forecast, By Region

      • 5.5.3. Market Share Analysis, By Country

    • 5.6. Others

      • 5.6.1. Key Market Trends, Growth Factors and Opportunities

      • 5.6.2. Market Size and Forecast, By Region

      • 5.6.3. Market Share Analysis, By Country

  • CHAPTER 6: GENE SEQUENCING MARKET, BY WORKFLOW TYPE

    • 6.1. Market Overview

      • 6.1.1 Market Size and Forecast, By Workflow Type

    • 6.2. Pre-Sequencing

      • 6.2.1. Key Market Trends, Growth Factors and Opportunities

      • 6.2.2. Market Size and Forecast, By Region

      • 6.2.3. Market Share Analysis, By Country

    • 6.3. Sequencing

      • 6.3.1. Key Market Trends, Growth Factors and Opportunities

      • 6.3.2. Market Size and Forecast, By Region

      • 6.3.3. Market Share Analysis, By Country

    • 6.4. Data Analysis

      • 6.4.1. Key Market Trends, Growth Factors and Opportunities

      • 6.4.2. Market Size and Forecast, By Region

      • 6.4.3. Market Share Analysis, By Country

  • CHAPTER 7: GENE SEQUENCING MARKET, BY END USER

    • 7.1. Market Overview

      • 7.1.1 Market Size and Forecast, By End User

    • 7.2. Academic Research

      • 7.2.1. Key Market Trends, Growth Factors and Opportunities

      • 7.2.2. Market Size and Forecast, By Region

      • 7.2.3. Market Share Analysis, By Country

    • 7.3. Clinical Research

      • 7.3.1. Key Market Trends, Growth Factors and Opportunities

      • 7.3.2. Market Size and Forecast, By Region

      • 7.3.3. Market Share Analysis, By Country

    • 7.4. Hospitals

      • 7.4.1. Key Market Trends, Growth Factors and Opportunities

      • 7.4.2. Market Size and Forecast, By Region

      • 7.4.3. Market Share Analysis, By Country

    • 7.5. Pharmaceutical Companies

      • 7.5.1. Key Market Trends, Growth Factors and Opportunities

      • 7.5.2. Market Size and Forecast, By Region

      • 7.5.3. Market Share Analysis, By Country

    • 7.6. Others

      • 7.6.1. Key Market Trends, Growth Factors and Opportunities

      • 7.6.2. Market Size and Forecast, By Region

      • 7.6.3. Market Share Analysis, By Country

  • CHAPTER 8: GENE SEQUENCING MARKET, BY REGION

    • 8.1. Market Overview

      • 8.1.1 Market Size and Forecast, By Region

    • 8.2. North America

      • 8.2.1. Key Market Trends and Opportunities

      • 8.2.2. Market Size and Forecast, By Product Type

      • 8.2.3. Market Size and Forecast, By Application

      • 8.2.4. Market Size and Forecast, By Workflow Type

      • 8.2.5. Market Size and Forecast, By End User

      • 8.2.6. Market Size and Forecast, By Country

      • 8.2.7. U.S. Gene Sequencing Market

        • 8.2.7.1. Market Size and Forecast, By Product Type
        • 8.2.7.2. Market Size and Forecast, By Application
        • 8.2.7.3. Market Size and Forecast, By Workflow Type
        • 8.2.7.4. Market Size and Forecast, By End User
      • 8.2.8. Canada Gene Sequencing Market

        • 8.2.8.1. Market Size and Forecast, By Product Type
        • 8.2.8.2. Market Size and Forecast, By Application
        • 8.2.8.3. Market Size and Forecast, By Workflow Type
        • 8.2.8.4. Market Size and Forecast, By End User
      • 8.2.9. Mexico Gene Sequencing Market

        • 8.2.9.1. Market Size and Forecast, By Product Type
        • 8.2.9.2. Market Size and Forecast, By Application
        • 8.2.9.3. Market Size and Forecast, By Workflow Type
        • 8.2.9.4. Market Size and Forecast, By End User
    • 8.3. Europe

      • 8.3.1. Key Market Trends and Opportunities

      • 8.3.2. Market Size and Forecast, By Product Type

      • 8.3.3. Market Size and Forecast, By Application

      • 8.3.4. Market Size and Forecast, By Workflow Type

      • 8.3.5. Market Size and Forecast, By End User

      • 8.3.6. Market Size and Forecast, By Country

      • 8.3.7. France Gene Sequencing Market

        • 8.3.7.1. Market Size and Forecast, By Product Type
        • 8.3.7.2. Market Size and Forecast, By Application
        • 8.3.7.3. Market Size and Forecast, By Workflow Type
        • 8.3.7.4. Market Size and Forecast, By End User
      • 8.3.8. Germany Gene Sequencing Market

        • 8.3.8.1. Market Size and Forecast, By Product Type
        • 8.3.8.2. Market Size and Forecast, By Application
        • 8.3.8.3. Market Size and Forecast, By Workflow Type
        • 8.3.8.4. Market Size and Forecast, By End User
      • 8.3.9. Italy Gene Sequencing Market

        • 8.3.9.1. Market Size and Forecast, By Product Type
        • 8.3.9.2. Market Size and Forecast, By Application
        • 8.3.9.3. Market Size and Forecast, By Workflow Type
        • 8.3.9.4. Market Size and Forecast, By End User
      • 8.3.10. Spain Gene Sequencing Market

        • 8.3.10.1. Market Size and Forecast, By Product Type
        • 8.3.10.2. Market Size and Forecast, By Application
        • 8.3.10.3. Market Size and Forecast, By Workflow Type
        • 8.3.10.4. Market Size and Forecast, By End User
      • 8.3.11. UK Gene Sequencing Market

        • 8.3.11.1. Market Size and Forecast, By Product Type
        • 8.3.11.2. Market Size and Forecast, By Application
        • 8.3.11.3. Market Size and Forecast, By Workflow Type
        • 8.3.11.4. Market Size and Forecast, By End User
      • 8.3.12. Russia Gene Sequencing Market

        • 8.3.12.1. Market Size and Forecast, By Product Type
        • 8.3.12.2. Market Size and Forecast, By Application
        • 8.3.12.3. Market Size and Forecast, By Workflow Type
        • 8.3.12.4. Market Size and Forecast, By End User
      • 8.3.13. Rest Of Europe Gene Sequencing Market

        • 8.3.13.1. Market Size and Forecast, By Product Type
        • 8.3.13.2. Market Size and Forecast, By Application
        • 8.3.13.3. Market Size and Forecast, By Workflow Type
        • 8.3.13.4. Market Size and Forecast, By End User
    • 8.4. Asia-Pacific

      • 8.4.1. Key Market Trends and Opportunities

      • 8.4.2. Market Size and Forecast, By Product Type

      • 8.4.3. Market Size and Forecast, By Application

      • 8.4.4. Market Size and Forecast, By Workflow Type

      • 8.4.5. Market Size and Forecast, By End User

      • 8.4.6. Market Size and Forecast, By Country

      • 8.4.7. China Gene Sequencing Market

        • 8.4.7.1. Market Size and Forecast, By Product Type
        • 8.4.7.2. Market Size and Forecast, By Application
        • 8.4.7.3. Market Size and Forecast, By Workflow Type
        • 8.4.7.4. Market Size and Forecast, By End User
      • 8.4.8. Japan Gene Sequencing Market

        • 8.4.8.1. Market Size and Forecast, By Product Type
        • 8.4.8.2. Market Size and Forecast, By Application
        • 8.4.8.3. Market Size and Forecast, By Workflow Type
        • 8.4.8.4. Market Size and Forecast, By End User
      • 8.4.9. India Gene Sequencing Market

        • 8.4.9.1. Market Size and Forecast, By Product Type
        • 8.4.9.2. Market Size and Forecast, By Application
        • 8.4.9.3. Market Size and Forecast, By Workflow Type
        • 8.4.9.4. Market Size and Forecast, By End User
      • 8.4.10. South Korea Gene Sequencing Market

        • 8.4.10.1. Market Size and Forecast, By Product Type
        • 8.4.10.2. Market Size and Forecast, By Application
        • 8.4.10.3. Market Size and Forecast, By Workflow Type
        • 8.4.10.4. Market Size and Forecast, By End User
      • 8.4.11. Australia Gene Sequencing Market

        • 8.4.11.1. Market Size and Forecast, By Product Type
        • 8.4.11.2. Market Size and Forecast, By Application
        • 8.4.11.3. Market Size and Forecast, By Workflow Type
        • 8.4.11.4. Market Size and Forecast, By End User
      • 8.4.12. Thailand Gene Sequencing Market

        • 8.4.12.1. Market Size and Forecast, By Product Type
        • 8.4.12.2. Market Size and Forecast, By Application
        • 8.4.12.3. Market Size and Forecast, By Workflow Type
        • 8.4.12.4. Market Size and Forecast, By End User
      • 8.4.13. Malaysia Gene Sequencing Market

        • 8.4.13.1. Market Size and Forecast, By Product Type
        • 8.4.13.2. Market Size and Forecast, By Application
        • 8.4.13.3. Market Size and Forecast, By Workflow Type
        • 8.4.13.4. Market Size and Forecast, By End User
      • 8.4.14. Indonesia Gene Sequencing Market

        • 8.4.14.1. Market Size and Forecast, By Product Type
        • 8.4.14.2. Market Size and Forecast, By Application
        • 8.4.14.3. Market Size and Forecast, By Workflow Type
        • 8.4.14.4. Market Size and Forecast, By End User
      • 8.4.15. Rest of Asia Pacific Gene Sequencing Market

        • 8.4.15.1. Market Size and Forecast, By Product Type
        • 8.4.15.2. Market Size and Forecast, By Application
        • 8.4.15.3. Market Size and Forecast, By Workflow Type
        • 8.4.15.4. Market Size and Forecast, By End User
    • 8.5. LAMEA

      • 8.5.1. Key Market Trends and Opportunities

      • 8.5.2. Market Size and Forecast, By Product Type

      • 8.5.3. Market Size and Forecast, By Application

      • 8.5.4. Market Size and Forecast, By Workflow Type

      • 8.5.5. Market Size and Forecast, By End User

      • 8.5.6. Market Size and Forecast, By Country

      • 8.5.7. Brazil Gene Sequencing Market

        • 8.5.7.1. Market Size and Forecast, By Product Type
        • 8.5.7.2. Market Size and Forecast, By Application
        • 8.5.7.3. Market Size and Forecast, By Workflow Type
        • 8.5.7.4. Market Size and Forecast, By End User
      • 8.5.8. South Africa Gene Sequencing Market

        • 8.5.8.1. Market Size and Forecast, By Product Type
        • 8.5.8.2. Market Size and Forecast, By Application
        • 8.5.8.3. Market Size and Forecast, By Workflow Type
        • 8.5.8.4. Market Size and Forecast, By End User
      • 8.5.9. Saudi Arabia Gene Sequencing Market

        • 8.5.9.1. Market Size and Forecast, By Product Type
        • 8.5.9.2. Market Size and Forecast, By Application
        • 8.5.9.3. Market Size and Forecast, By Workflow Type
        • 8.5.9.4. Market Size and Forecast, By End User
      • 8.5.10. UAE Gene Sequencing Market

        • 8.5.10.1. Market Size and Forecast, By Product Type
        • 8.5.10.2. Market Size and Forecast, By Application
        • 8.5.10.3. Market Size and Forecast, By Workflow Type
        • 8.5.10.4. Market Size and Forecast, By End User
      • 8.5.11. Argentina Gene Sequencing Market

        • 8.5.11.1. Market Size and Forecast, By Product Type
        • 8.5.11.2. Market Size and Forecast, By Application
        • 8.5.11.3. Market Size and Forecast, By Workflow Type
        • 8.5.11.4. Market Size and Forecast, By End User
      • 8.5.12. Rest of LAMEA Gene Sequencing Market

        • 8.5.12.1. Market Size and Forecast, By Product Type
        • 8.5.12.2. Market Size and Forecast, By Application
        • 8.5.12.3. Market Size and Forecast, By Workflow Type
        • 8.5.12.4. Market Size and Forecast, By End User
  • CHAPTER 9: COMPETITIVE LANDSCAPE

    • 9.1. Introduction

    • 9.2. Top Winning Strategies

    • 9.3. Product Mapping Of Top 10 Player

    • 9.4. Competitive Dashboard

    • 9.5. Competitive Heatmap

    • 9.6. Top Player Positioning, 2024

  • CHAPTER 10: COMPANY PROFILES

    • 10.1. Agilent Technologies, Inc.

      • 10.1.1. Company Overview

      • 10.1.2. Key Executives

      • 10.1.3. Company Snapshot

      • 10.1.4. Operating Business Segments

      • 10.1.5. Product Portfolio

      • 10.1.6. Business Performance

      • 10.1.7. Key Strategic Moves and Developments

    • 10.2. Thermo Fisher Scientific, Inc.

      • 10.2.1. Company Overview

      • 10.2.2. Key Executives

      • 10.2.3. Company Snapshot

      • 10.2.4. Operating Business Segments

      • 10.2.5. Product Portfolio

      • 10.2.6. Business Performance

      • 10.2.7. Key Strategic Moves and Developments

    • 10.3. Illumina, Inc.

      • 10.3.1. Company Overview

      • 10.3.2. Key Executives

      • 10.3.3. Company Snapshot

      • 10.3.4. Operating Business Segments

      • 10.3.5. Product Portfolio

      • 10.3.6. Business Performance

      • 10.3.7. Key Strategic Moves and Developments

    • 10.4. Pacific Biosciences Of California, Inc.

      • 10.4.1. Company Overview

      • 10.4.2. Key Executives

      • 10.4.3. Company Snapshot

      • 10.4.4. Operating Business Segments

      • 10.4.5. Product Portfolio

      • 10.4.6. Business Performance

      • 10.4.7. Key Strategic Moves and Developments

    • 10.5. QIAGEN

      • 10.5.1. Company Overview

      • 10.5.2. Key Executives

      • 10.5.3. Company Snapshot

      • 10.5.4. Operating Business Segments

      • 10.5.5. Product Portfolio

      • 10.5.6. Business Performance

      • 10.5.7. Key Strategic Moves and Developments

    • 10.6. F. Hoffmann-La Roche Ltd.

      • 10.6.1. Company Overview

      • 10.6.2. Key Executives

      • 10.6.3. Company Snapshot

      • 10.6.4. Operating Business Segments

      • 10.6.5. Product Portfolio

      • 10.6.6. Business Performance

      • 10.6.7. Key Strategic Moves and Developments

    • 10.7. Myriad Genetics

      • 10.7.1. Company Overview

      • 10.7.2. Key Executives

      • 10.7.3. Company Snapshot

      • 10.7.4. Operating Business Segments

      • 10.7.5. Product Portfolio

      • 10.7.6. Business Performance

      • 10.7.7. Key Strategic Moves and Developments

    • 10.8. PierianDx

      • 10.8.1. Company Overview

      • 10.8.2. Key Executives

      • 10.8.3. Company Snapshot

      • 10.8.4. Operating Business Segments

      • 10.8.5. Product Portfolio

      • 10.8.6. Business Performance

      • 10.8.7. Key Strategic Moves and Developments

    • 10.9. Eurofins Scientific

      • 10.9.1. Company Overview

      • 10.9.2. Key Executives

      • 10.9.3. Company Snapshot

      • 10.9.4. Operating Business Segments

      • 10.9.5. Product Portfolio

      • 10.9.6. Business Performance

      • 10.9.7. Key Strategic Moves and Developments

    • 10.10. Intrexon Bioinformatics Germany GmbH

      • 10.10.1. Company Overview

      • 10.10.2. Key Executives

      • 10.10.3. Company Snapshot

      • 10.10.4. Operating Business Segments

      • 10.10.5. Product Portfolio

      • 10.10.6. Business Performance

      • 10.10.7. Key Strategic Moves and Developments

  • LIST OF TABLES

  • TABLE 1. GLOBAL GENE SEQUENCING MARKET, BY PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 2. GLOBAL GENE SEQUENCING MARKET FOR CONSUMABLES, BY REGION, 2025-2033 ($MILLION)
  • TABLE 3. GLOBAL GENE SEQUENCING MARKET FOR INSTRUMENTS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 4. GLOBAL GENE SEQUENCING MARKET FOR SERVICES, BY REGION, 2025-2033 ($MILLION)
  • TABLE 5. GLOBAL GENE SEQUENCING MARKET, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 6. GLOBAL GENE SEQUENCING MARKET FOR ONCOLOGY AND REPRODUCTIVE HEALTH, BY REGION, 2025-2033 ($MILLION)
  • TABLE 7. GLOBAL GENE SEQUENCING MARKET FOR CLINICAL INVESTIGATION, BY REGION, 2025-2033 ($MILLION)
  • TABLE 8. GLOBAL GENE SEQUENCING MARKET FOR CONSUMER GENOMICS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 9. GLOBAL GENE SEQUENCING MARKET FOR METAGENOMICS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 10. GLOBAL GENE SEQUENCING MARKET FOR OTHERS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 11. GLOBAL GENE SEQUENCING MARKET, BY WORKFLOW TYPE, 2025-2033 ($MILLION)
  • TABLE 12. GLOBAL GENE SEQUENCING MARKET FOR PRE-SEQUENCING, BY REGION, 2025-2033 ($MILLION)
  • TABLE 13. GLOBAL GENE SEQUENCING MARKET FOR SEQUENCING, BY REGION, 2025-2033 ($MILLION)
  • TABLE 14. GLOBAL GENE SEQUENCING MARKET FOR DATA ANALYSIS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 15. GLOBAL GENE SEQUENCING MARKET, BY END USER, 2025-2033 ($MILLION)
  • TABLE 16. GLOBAL GENE SEQUENCING MARKET FOR ACADEMIC RESEARCH, BY REGION, 2025-2033 ($MILLION)
  • TABLE 17. GLOBAL GENE SEQUENCING MARKET FOR CLINICAL RESEARCH, BY REGION, 2025-2033 ($MILLION)
  • TABLE 18. GLOBAL GENE SEQUENCING MARKET FOR HOSPITALS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 19. GLOBAL GENE SEQUENCING MARKET FOR PHARMACEUTICAL COMPANIES, BY REGION, 2025-2033 ($MILLION)
  • TABLE 20. GLOBAL GENE SEQUENCING MARKET FOR OTHERS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 21. GLOBAL GENE SEQUENCING MARKET, BY REGION, 2025-2033 ($MILLION)
  • TABLE 22. NORTH AMERICA GENE SEQUENCING, BY REGION, 2025-2033 ($MILLION)
  • TABLE 23. NORTH AMERICA GENE SEQUENCING, BY PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 24. NORTH AMERICA GENE SEQUENCING, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 25. NORTH AMERICA GENE SEQUENCING, BY WORKFLOW TYPE, 2025-2033 ($MILLION)
  • TABLE 26. NORTH AMERICA GENE SEQUENCING, BY END USER, 2025-2033 ($MILLION)
  • TABLE 27. U.S. GENE SEQUENCING, BY PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 28. U.S. GENE SEQUENCING, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 29. U.S. GENE SEQUENCING, BY WORKFLOW TYPE, 2025-2033 ($MILLION)
  • TABLE 30. U.S. GENE SEQUENCING, BY END USER, 2025-2033 ($MILLION)
  • TABLE 31. CANADA GENE SEQUENCING, BY PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 32. CANADA GENE SEQUENCING, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 33. CANADA GENE SEQUENCING, BY WORKFLOW TYPE, 2025-2033 ($MILLION)
  • TABLE 34. CANADA GENE SEQUENCING, BY END USER, 2025-2033 ($MILLION)
  • TABLE 35. MEXICO GENE SEQUENCING, BY PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 36. MEXICO GENE SEQUENCING, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 37. MEXICO GENE SEQUENCING, BY WORKFLOW TYPE, 2025-2033 ($MILLION)
  • TABLE 38. MEXICO GENE SEQUENCING, BY END USER, 2025-2033 ($MILLION)
  • TABLE 39. EUROPE GENE SEQUENCING, BY REGION, 2025-2033 ($MILLION)
  • TABLE 40. EUROPE GENE SEQUENCING, BY PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 41. EUROPE GENE SEQUENCING, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 42. EUROPE GENE SEQUENCING, BY WORKFLOW TYPE, 2025-2033 ($MILLION)
  • TABLE 43. EUROPE GENE SEQUENCING, BY END USER, 2025-2033 ($MILLION)
  • TABLE 44. FRANCE GENE SEQUENCING, BY PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 45. FRANCE GENE SEQUENCING, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 46. FRANCE GENE SEQUENCING, BY WORKFLOW TYPE, 2025-2033 ($MILLION)
  • TABLE 47. FRANCE GENE SEQUENCING, BY END USER, 2025-2033 ($MILLION)
  • TABLE 48. GERMANY GENE SEQUENCING, BY PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 49. GERMANY GENE SEQUENCING, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 50. GERMANY GENE SEQUENCING, BY WORKFLOW TYPE, 2025-2033 ($MILLION)
  • TABLE 51. GERMANY GENE SEQUENCING, BY END USER, 2025-2033 ($MILLION)
  • TABLE 52. ITALY GENE SEQUENCING, BY PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 53. ITALY GENE SEQUENCING, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 54. ITALY GENE SEQUENCING, BY WORKFLOW TYPE, 2025-2033 ($MILLION)
  • TABLE 55. ITALY GENE SEQUENCING, BY END USER, 2025-2033 ($MILLION)
  • TABLE 56. SPAIN GENE SEQUENCING, BY PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 57. SPAIN GENE SEQUENCING, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 58. SPAIN GENE SEQUENCING, BY WORKFLOW TYPE, 2025-2033 ($MILLION)
  • TABLE 59. SPAIN GENE SEQUENCING, BY END USER, 2025-2033 ($MILLION)
  • TABLE 60. UK GENE SEQUENCING, BY PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 61. UK GENE SEQUENCING, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 62. UK GENE SEQUENCING, BY WORKFLOW TYPE, 2025-2033 ($MILLION)
  • TABLE 63. UK GENE SEQUENCING, BY END USER, 2025-2033 ($MILLION)
  • TABLE 64. RUSSIA GENE SEQUENCING, BY PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 65. RUSSIA GENE SEQUENCING, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 66. RUSSIA GENE SEQUENCING, BY WORKFLOW TYPE, 2025-2033 ($MILLION)
  • TABLE 67. RUSSIA GENE SEQUENCING, BY END USER, 2025-2033 ($MILLION)
  • TABLE 68. REST OF EUROPE GENE SEQUENCING, BY PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 69. REST OF EUROPE GENE SEQUENCING, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 70. REST OF EUROPE GENE SEQUENCING, BY WORKFLOW TYPE, 2025-2033 ($MILLION)
  • TABLE 71. REST OF EUROPE GENE SEQUENCING, BY END USER, 2025-2033 ($MILLION)
  • TABLE 72. ASIA-PACIFIC GENE SEQUENCING, BY REGION, 2025-2033 ($MILLION)
  • TABLE 73. ASIA-PACIFIC GENE SEQUENCING, BY PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 74. ASIA-PACIFIC GENE SEQUENCING, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 75. ASIA-PACIFIC GENE SEQUENCING, BY WORKFLOW TYPE, 2025-2033 ($MILLION)
  • TABLE 76. ASIA-PACIFIC GENE SEQUENCING, BY END USER, 2025-2033 ($MILLION)
  • TABLE 77. CHINA GENE SEQUENCING, BY PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 78. CHINA GENE SEQUENCING, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 79. CHINA GENE SEQUENCING, BY WORKFLOW TYPE, 2025-2033 ($MILLION)
  • TABLE 80. CHINA GENE SEQUENCING, BY END USER, 2025-2033 ($MILLION)
  • TABLE 81. JAPAN GENE SEQUENCING, BY PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 82. JAPAN GENE SEQUENCING, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 83. JAPAN GENE SEQUENCING, BY WORKFLOW TYPE, 2025-2033 ($MILLION)
  • TABLE 84. JAPAN GENE SEQUENCING, BY END USER, 2025-2033 ($MILLION)
  • TABLE 85. INDIA GENE SEQUENCING, BY PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 86. INDIA GENE SEQUENCING, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 87. INDIA GENE SEQUENCING, BY WORKFLOW TYPE, 2025-2033 ($MILLION)
  • TABLE 88. INDIA GENE SEQUENCING, BY END USER, 2025-2033 ($MILLION)
  • TABLE 89. SOUTH KOREA GENE SEQUENCING, BY PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 90. SOUTH KOREA GENE SEQUENCING, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 91. SOUTH KOREA GENE SEQUENCING, BY WORKFLOW TYPE, 2025-2033 ($MILLION)
  • TABLE 92. SOUTH KOREA GENE SEQUENCING, BY END USER, 2025-2033 ($MILLION)
  • TABLE 93. AUSTRALIA GENE SEQUENCING, BY PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 94. AUSTRALIA GENE SEQUENCING, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 95. AUSTRALIA GENE SEQUENCING, BY WORKFLOW TYPE, 2025-2033 ($MILLION)
  • TABLE 96. AUSTRALIA GENE SEQUENCING, BY END USER, 2025-2033 ($MILLION)
  • TABLE 97. THAILAND GENE SEQUENCING, BY PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 98. THAILAND GENE SEQUENCING, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 99. THAILAND GENE SEQUENCING, BY WORKFLOW TYPE, 2025-2033 ($MILLION)
  • TABLE 100. THAILAND GENE SEQUENCING, BY END USER, 2025-2033 ($MILLION)
  • TABLE 101. MALAYSIA GENE SEQUENCING, BY PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 102. MALAYSIA GENE SEQUENCING, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 103. MALAYSIA GENE SEQUENCING, BY WORKFLOW TYPE, 2025-2033 ($MILLION)
  • TABLE 104. MALAYSIA GENE SEQUENCING, BY END USER, 2025-2033 ($MILLION)
  • TABLE 105. INDONESIA GENE SEQUENCING, BY PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 106. INDONESIA GENE SEQUENCING, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 107. INDONESIA GENE SEQUENCING, BY WORKFLOW TYPE, 2025-2033 ($MILLION)
  • TABLE 108. INDONESIA GENE SEQUENCING, BY END USER, 2025-2033 ($MILLION)
  • TABLE 109. REST OF ASIA PACIFIC GENE SEQUENCING, BY PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 110. REST OF ASIA PACIFIC GENE SEQUENCING, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 111. REST OF ASIA PACIFIC GENE SEQUENCING, BY WORKFLOW TYPE, 2025-2033 ($MILLION)
  • TABLE 112. REST OF ASIA PACIFIC GENE SEQUENCING, BY END USER, 2025-2033 ($MILLION)
  • TABLE 113. LAMEA GENE SEQUENCING, BY REGION, 2025-2033 ($MILLION)
  • TABLE 114. LAMEA GENE SEQUENCING, BY PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 115. LAMEA GENE SEQUENCING, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 116. LAMEA GENE SEQUENCING, BY WORKFLOW TYPE, 2025-2033 ($MILLION)
  • TABLE 117. LAMEA GENE SEQUENCING, BY END USER, 2025-2033 ($MILLION)
  • TABLE 118. BRAZIL GENE SEQUENCING, BY PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 119. BRAZIL GENE SEQUENCING, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 120. BRAZIL GENE SEQUENCING, BY WORKFLOW TYPE, 2025-2033 ($MILLION)
  • TABLE 121. BRAZIL GENE SEQUENCING, BY END USER, 2025-2033 ($MILLION)
  • TABLE 122. SOUTH AFRICA GENE SEQUENCING, BY PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 123. SOUTH AFRICA GENE SEQUENCING, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 124. SOUTH AFRICA GENE SEQUENCING, BY WORKFLOW TYPE, 2025-2033 ($MILLION)
  • TABLE 125. SOUTH AFRICA GENE SEQUENCING, BY END USER, 2025-2033 ($MILLION)
  • TABLE 126. SAUDI ARABIA GENE SEQUENCING, BY PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 127. SAUDI ARABIA GENE SEQUENCING, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 128. SAUDI ARABIA GENE SEQUENCING, BY WORKFLOW TYPE, 2025-2033 ($MILLION)
  • TABLE 129. SAUDI ARABIA GENE SEQUENCING, BY END USER, 2025-2033 ($MILLION)
  • TABLE 130. UAE GENE SEQUENCING, BY PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 131. UAE GENE SEQUENCING, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 132. UAE GENE SEQUENCING, BY WORKFLOW TYPE, 2025-2033 ($MILLION)
  • TABLE 133. UAE GENE SEQUENCING, BY END USER, 2025-2033 ($MILLION)
  • TABLE 134. ARGENTINA GENE SEQUENCING, BY PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 135. ARGENTINA GENE SEQUENCING, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 136. ARGENTINA GENE SEQUENCING, BY WORKFLOW TYPE, 2025-2033 ($MILLION)
  • TABLE 137. ARGENTINA GENE SEQUENCING, BY END USER, 2025-2033 ($MILLION)
  • TABLE 138. REST OF LAMEA GENE SEQUENCING, BY PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 139. REST OF LAMEA GENE SEQUENCING, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 140. REST OF LAMEA GENE SEQUENCING, BY WORKFLOW TYPE, 2025-2033 ($MILLION)
  • TABLE 141. REST OF LAMEA GENE SEQUENCING, BY END USER, 2025-2033 ($MILLION)
  • TABLE 142. AGILENT TECHNOLOGIES, INC.: KEY EXECUTIVES
  • TABLE 143. AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT
  • TABLE 144. AGILENT TECHNOLOGIES, INC.: OPERATING SEGMENTS
  • TABLE 145. AGILENT TECHNOLOGIES, INC.: PRODUCT PORTFOLIO
  • TABLE 146. AGILENT TECHNOLOGIES, INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 147. THERMO FISHER SCIENTIFIC, INC.: KEY EXECUTIVES
  • TABLE 148. THERMO FISHER SCIENTIFIC, INC.: COMPANY SNAPSHOT
  • TABLE 149. THERMO FISHER SCIENTIFIC, INC.: OPERATING SEGMENTS
  • TABLE 150. THERMO FISHER SCIENTIFIC, INC.: PRODUCT PORTFOLIO
  • TABLE 151. THERMO FISHER SCIENTIFIC, INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 152. ILLUMINA, INC.: KEY EXECUTIVES
  • TABLE 153. ILLUMINA, INC.: COMPANY SNAPSHOT
  • TABLE 154. ILLUMINA, INC.: OPERATING SEGMENTS
  • TABLE 155. ILLUMINA, INC.: PRODUCT PORTFOLIO
  • TABLE 156. ILLUMINA, INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 157. PACIFIC BIOSCIENCES OF CALIFORNIA, INC.: KEY EXECUTIVES
  • TABLE 158. PACIFIC BIOSCIENCES OF CALIFORNIA, INC.: COMPANY SNAPSHOT
  • TABLE 159. PACIFIC BIOSCIENCES OF CALIFORNIA, INC.: OPERATING SEGMENTS
  • TABLE 160. PACIFIC BIOSCIENCES OF CALIFORNIA, INC.: PRODUCT PORTFOLIO
  • TABLE 161. PACIFIC BIOSCIENCES OF CALIFORNIA, INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 162. QIAGEN: KEY EXECUTIVES
  • TABLE 163. QIAGEN: COMPANY SNAPSHOT
  • TABLE 164. QIAGEN: OPERATING SEGMENTS
  • TABLE 165. QIAGEN: PRODUCT PORTFOLIO
  • TABLE 166. QIAGEN: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 167. F. HOFFMANN-LA ROCHE LTD.: KEY EXECUTIVES
  • TABLE 168. F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT
  • TABLE 169. F. HOFFMANN-LA ROCHE LTD.: OPERATING SEGMENTS
  • TABLE 170. F. HOFFMANN-LA ROCHE LTD.: PRODUCT PORTFOLIO
  • TABLE 171. F. HOFFMANN-LA ROCHE LTD.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 172. MYRIAD GENETICS: KEY EXECUTIVES
  • TABLE 173. MYRIAD GENETICS: COMPANY SNAPSHOT
  • TABLE 174. MYRIAD GENETICS: OPERATING SEGMENTS
  • TABLE 175. MYRIAD GENETICS: PRODUCT PORTFOLIO
  • TABLE 176. MYRIAD GENETICS: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 177. PIERIANDX: KEY EXECUTIVES
  • TABLE 178. PIERIANDX: COMPANY SNAPSHOT
  • TABLE 179. PIERIANDX: OPERATING SEGMENTS
  • TABLE 180. PIERIANDX: PRODUCT PORTFOLIO
  • TABLE 181. PIERIANDX: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 182. EUROFINS SCIENTIFIC: KEY EXECUTIVES
  • TABLE 183. EUROFINS SCIENTIFIC: COMPANY SNAPSHOT
  • TABLE 184. EUROFINS SCIENTIFIC: OPERATING SEGMENTS
  • TABLE 185. EUROFINS SCIENTIFIC: PRODUCT PORTFOLIO
  • TABLE 186. EUROFINS SCIENTIFIC: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 187. INTREXON BIOINFORMATICS GERMANY GMBH: KEY EXECUTIVES
  • TABLE 188. INTREXON BIOINFORMATICS GERMANY GMBH: COMPANY SNAPSHOT
  • TABLE 189. INTREXON BIOINFORMATICS GERMANY GMBH: OPERATING SEGMENTS
  • TABLE 190. INTREXON BIOINFORMATICS GERMANY GMBH: PRODUCT PORTFOLIO
  • TABLE 191. INTREXON BIOINFORMATICS GERMANY GMBH: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • LIST OF FIGURES

  • FIGURE 1. GLOBAL GENE SEQUENCING MARKET SEGMENTATION
  • FIGURE 2. GLOBAL GENE SEQUENCING MARKET
  • FIGURE 3. SEGMENTATION GENE SEQUENCING MARKET
  • FIGURE 4. TOP INVESTMENT POCKET IN GENE SEQUENCING MARKET
  • FIGURE 5. MODERATE BARGAINING POWER OF BUYERS
  • FIGURE 6. MODERATE BARGAINING POWER OF SUPPLIERS
  • FIGURE 7. MODERATE THREAT OF NEW ENTRANTS
  • FIGURE 8. LOW THREAT OF SUBSTITUTION
  • FIGURE 9. HIGH COMPETITIVE RIVALRY
  • FIGURE 10. OPPORTUNITIES, RESTRAINTS AND DRIVERS: GLOBALGENE SEQUENCING MARKET
  • FIGURE 11. GENE SEQUENCING MARKET SEGMENTATION, BY BY PRODUCT TYPE
  • FIGURE 12. GENE SEQUENCING MARKET FOR CONSUMABLES, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 13. GENE SEQUENCING MARKET FOR INSTRUMENTS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 14. GENE SEQUENCING MARKET FOR SERVICES, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 15. GENE SEQUENCING MARKET SEGMENTATION, BY BY APPLICATION
  • FIGURE 16. GENE SEQUENCING MARKET FOR ONCOLOGY AND REPRODUCTIVE HEALTH, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 17. GENE SEQUENCING MARKET FOR CLINICAL INVESTIGATION, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 18. GENE SEQUENCING MARKET FOR CONSUMER GENOMICS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 19. GENE SEQUENCING MARKET FOR METAGENOMICS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 20. GENE SEQUENCING MARKET FOR OTHERS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 21. GENE SEQUENCING MARKET SEGMENTATION, BY BY WORKFLOW TYPE
  • FIGURE 22. GENE SEQUENCING MARKET FOR PRE-SEQUENCING, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 23. GENE SEQUENCING MARKET FOR SEQUENCING, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 24. GENE SEQUENCING MARKET FOR DATA ANALYSIS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 25. GENE SEQUENCING MARKET SEGMENTATION, BY BY END USER
  • FIGURE 26. GENE SEQUENCING MARKET FOR ACADEMIC RESEARCH, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 27. GENE SEQUENCING MARKET FOR CLINICAL RESEARCH, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 28. GENE SEQUENCING MARKET FOR HOSPITALS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 29. GENE SEQUENCING MARKET FOR PHARMACEUTICAL COMPANIES, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 30. GENE SEQUENCING MARKET FOR OTHERS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 31. TOP WINNING STRATEGIES, BY YEAR, 2022-2024*
  • FIGURE 32. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2022-2024*
  • FIGURE 33. TOP WINNING STRATEGIES, BY COMPANY, 2022-2024*
  • FIGURE 34. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 35. COMPETITIVE DASHBOARD
  • FIGURE 36. COMPETITIVE HEATMAP: GENE SEQUENCING MARKET
  • FIGURE 37. TOP PLAYER POSITIONING, 2024
  • FIGURE 38. AGILENT TECHNOLOGIES, INC.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 39. AGILENT TECHNOLOGIES, INC.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 40. AGILENT TECHNOLOGIES, INC.: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 41. THERMO FISHER SCIENTIFIC, INC.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 42. THERMO FISHER SCIENTIFIC, INC.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 43. THERMO FISHER SCIENTIFIC, INC.: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 44. ILLUMINA, INC.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 45. ILLUMINA, INC.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 46. ILLUMINA, INC.: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 47. PACIFIC BIOSCIENCES OF CALIFORNIA, INC.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 48. PACIFIC BIOSCIENCES OF CALIFORNIA, INC.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 49. PACIFIC BIOSCIENCES OF CALIFORNIA, INC.: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 50. QIAGEN: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 51. QIAGEN: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 52. QIAGEN: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 53. F. HOFFMANN-LA ROCHE LTD.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 54. F. HOFFMANN-LA ROCHE LTD.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 55. F. HOFFMANN-LA ROCHE LTD.: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 56. MYRIAD GENETICS: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 57. MYRIAD GENETICS: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 58. MYRIAD GENETICS: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 59. PIERIANDX: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 60. PIERIANDX: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 61. PIERIANDX: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 62. EUROFINS SCIENTIFIC: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 63. EUROFINS SCIENTIFIC: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 64. EUROFINS SCIENTIFIC: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 65. INTREXON BIOINFORMATICS GERMANY GMBH: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 66. INTREXON BIOINFORMATICS GERMANY GMBH: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 67. INTREXON BIOINFORMATICS GERMANY GMBH: REVENUE SHARE, BY REGION, 2024 (%)

Purchase Full Report of
Gene Sequencing Market

PURCHASE OPTIONS



* Taxes/Fees, If applicable will be added during checkout. All prices in USD.

Have a question ?

Need to add more ?

Avail up to 30% discount on subscription plans on


Avenue